The research and development of anti-tumor drugs in China has entered a new era with strong growth

China's pharmaceutical market has grown steadily in recent years, with data showing that the Chinese pharmaceutical market has grown at a compound annual rate of 7.5% since 2015, reaching RMB1633 billion in 2019.
, tumors are the main therapeutic areas in Which China's pharmaceutical market is growing rapidly, accounting for 16.5% of the total size of China's pharmaceutical market in 2019.
The number of new cancer cases in China is increasing, driven by a number of factors, with data showing that the number of cases increased from 4 million in 2015 to 4.4 million in 2019, a compound annual growth rate of 2.7%.
, the field of oncology drugs has a relatively large room for growth.
understand that China's cancer drug market is growing much faster than China's new cancer cases, and is expected to continue to maintain a strong growth rate.
2015, China's oncology drug market was RMB110.2 billion, accounting for 9.0% of China's overall pharmaceutical market, and in 2019, China's oncology drug market reached RMB182.7 billion, accounting for 11.2% of China's pharmaceutical market, with a compound annual growth rate of 13.5% from 2015 to 2019.
first half of this year, the pharmaceutical industry showed a boom, despite varying degrees of impact from the outbreak.
According to data disclosed by the Drug Review Center of the State Drug Administration at the 2020 annual meeting of the Chinese Society of Clinical Oncology, the number of new anti-tumor drug approvals will increase over the same period in 2020, from 15 to 19, while the proportion of domestic varieties has increased from 26% to 47%.
In addition, industry sources pointed out that the new anti-tumor drug approved for sale in 2020 has its own characteristics, one is the domestic ADC drug was approved, the other is in small cell lung cancer in the long-difficult field of immunotherapy approval, and the third generation of domestic independent intellectual property rights of the third generation of TKI innovative drugs were approved.
, immunotherapy drugs for tumors such as esophageal cancer and stomach cancer have been approved.
In recent years, with the innovation drug review and approval and health insurance payment, more and more enterprises into innovative drug research and development, rich research and development pipeline, and actively promote more and more adaptive disorders into the clinical, in this context, China's cancer drugs also ushered in good.
the next 10 years, the field of anti-tumor drugs will continue to grow rapidly.
face changing market demands, pharmaceutical companies also need to make positive changes.
report that despite the success of anti-tumor drugs over the past 50 years, there are still many unsealed needs.
in the next 10 years, anti-tumor drugs will still account for a large share of the drug market, but the competition between enterprises will be more intense.
anti-tumor drug market will also cover a variety of different adaptations, companies will pay more attention to drug research and development and innovation.
Taking new cell and gene therapies as an example, in the past five years, new treatments such as cell therapy, viral vectors, RNA therapy and stem cell therapy have made remarkable advances and received increasing attention, especially with the approval of two CAR-T products, Kymriah and Yescarta.
the current market approved CAR-T products are not many, but there are now more than hundreds of products in the process of research and development, the future market growth potential is great.
the rise of cellular and gene therapy will change the existing models of pharmaceutical companies because they put higher demands on the corresponding production processes and supply chain systems.
addition, how to develop more effective treatment options, how to find the right time to enter the market are pharmaceutical companies have to face the problem.
these issues will allow pharmaceutical companies to make corresponding changes in research and development and business models.
recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of tumors, and the invention and application of advanced technologies such as large-scale rapid screening, combined chemistry and genetic engineering have accelerated the process of drug development.
industry said that with the continuous progress of technology and the introduction of a series of national policies, anti-tumor drug research and development has entered a new era.